The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 9,925 | 2,843,893 | SH | SOLE | 2,843,893 | 0 | 0 | ||
| Cytokinetics Incorporated | COM | 23282W605 | 37,884 | 1,607,292 | SH | SOLE | 1,607,292 | 0 | 0 | ||
| Dicerna Pharmaceuticals, Inc. | COM | 253031108 | 635 | 25,000 | SH | SOLE | 25,000 | 0 | 0 | ||
| Fulcrum Therapeutics, Inc. | COM | 359616109 | 20,740 | 1,133,948 | SH | SOLE | 1,133,948 | 0 | 0 | ||
| Generation Bio Co. | COM | 37148K100 | 18,017 | 857,942 | SH | SOLE | 857,942 | 0 | 0 | ||
| Keros Therapeutics, Inc. | COM | 492327101 | 53,567 | 1,428,071 | SH | SOLE | 1,428,071 | 0 | 0 | ||
| Kura Oncology, Inc. | COM | 50127T109 | 21,320 | 1,307,982 | SH | SOLE | 1,307,982 | 0 | 0 | ||
| Myokardia, Inc. | COM | 62857M105 | 12,222 | 126,492 | SH | SOLE | 126,492 | 0 | 0 | ||
| Oric Pharmaceuticals, Inc. | COM | 68622P109 | 4,216 | 125,000 | SH | SOLE | 125,000 | 0 | 0 | ||
| Retrophin, Inc. | COM | 761299106 | 612 | 30,000 | SH | SOLE | 30,000 | 0 | 0 | ||
| Vaxcyte, Inc. | COM | 92243G108 | 19,624 | 620,821 | SH | SOLE | 620,821 | 0 | 0 | ||
| Voyager Therapeutics, Inc. | COM | 92915B106 | 6,521 | 516,751 | SH | SOLE | 516,751 | 0 | 0 | ||